TESARO Fund Company Profile

Description

TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor to treat ovarian or breast cancers; and TSR-011, an anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients. The company also offers KEYTRUDA and OPDIVO, an anti-PD-1 antibody products, for the treatment of certain non-small cell lung cancers; and develops immunotherapy antibody product candidates targeting PD-1 (TSR-042) and TIM-3 (TSR-022), as well as LAG-3 and bi-specific antibody product candidates targeting PD-1/TIM-3, PD-1/LAG-3, and an additional bi-specific combination to treat various tumors. It has strategic research collaboration with Myriad Genetics, Inc.; and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development and commercialization of Niraparib to treat breast cancer patients. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.